1.Preoperative Serum Copeptin Can Predict Delayed Hyponatremia after Pituitary Surgery in the Absence of Arginine Vasopressin Deficiency
Ho KANG ; Seung Shin PARK ; Yoo Hyung KIM ; Hwan Sub LIM ; Mi-Kyeong LEE ; Kyoung-Ryul LEE ; Jung Hee KIM ; Yong Hwy KIM
Endocrinology and Metabolism 2024;39(1):164-175
Background:
Delayed postoperative hyponatremia (DPH) is the most common cause of readmission after pituitary surgery. In this study, we aimed to evaluate the cutoff values of serum copeptin and determine the optimal timing for copeptin measurement for the prediction of the occurrence of DPH in patients who undergo endoscopic transsphenoidal approach (eTSA) surgery and tumor resection.
Methods:
This was a prospective observational study of 73 patients who underwent eTSA surgery for pituitary or stalk lesions. Copeptin levels were measured before surgery, 1 hour after extubation, and on postoperative days 1, 2, 7, and 90.
Results:
Among 73 patients, 23 patients (31.5%) developed DPH. The baseline ratio of copeptin to serum sodium level showed the highest predictive performance (area under the curve [AUROC], 0.699), and its optimal cutoff to maximize Youden’s index was 2.5×10–11, with a sensitivity of 91.3% and negative predictive value of 92.0%. No significant predictors were identified for patients with transient arginine vasopressin (AVP) deficiency. However, for patients without transient AVP deficiency, the copeptin-to-urine osmolarity ratio at baseline demonstrated the highest predictive performance (AUROC, 0.725). An optimal cutoff of 6.5×10–12 maximized Youden’s index, with a sensitivity of 92.9% and a negative predictive value of 94.1%.
Conclusion
The occurrence of DPH can be predicted using baseline copeptin and its ratio with serum sodium or urine osmolarity only in patients without transient AVP deficiency after pituitary surgery.
2.Differences in Type 2 Fiber Composition in the Vastus Lateralis and Gluteus Maximus of Patients with Hip Fractures
Jingwen TIAN ; Minchul SONG ; Kyu Jeong CHO ; Ho Yeop LEE ; Sang Hyeon JU ; Jung Ryul LIM ; Ha Thi NGA ; Thi Linh NGUYEN ; Ji Sun MOON ; Hyo Ju JANG ; Jung-Mo HWANG ; Hyon-Seung YI
Endocrinology and Metabolism 2024;39(3):521-530
Background:
Aging leads to sarcopenia, which is characterized by reduced muscle mass and strength. Many factors, including altered muscle protein turnover, diminished neuromuscular function, hormonal changes, systemic inflammation, and the structure and composition of muscle fibers, play a crucial role in age-related muscle decline. This study explored differences in muscle fiber types contributing to overall muscle function decline in aging, focusing on individuals with hip fractures from falls.
Methods:
A pilot study at Chungnam National University Hospital collected muscle biopsies from hip fracture patients aged 20 to 80 undergoing surgical treatment. Muscle biopsies from the vastus lateralis and gluteus maximus were obtained during hip arthroplasty or internal fixation. Handgrip strength, calf and thigh circumference, and bone mineral density were evaluated in individuals with hip fractures from falls. We analyzed the relationships between each clinical characteristic and muscle fiber type.
Results:
In total, 26 participants (mean age 67.9 years, 69.2% male) were included in this study. The prevalence of sarcopenia was 53.8%, and that of femoral and lumbar osteoporosis was 19.2% and 11.5%, respectively. Vastus lateralis analysis revealed an age-related decrease in type IIx fibers, a higher proportion of type IIa fibers in women, and an association between handgrip strength and type IIx fibers in men. The gluteus maximus showed no significant correlations with clinical parameters.
Conclusion
This study identified complex associations between age, sex, handgrip strength, and muscle fiber composition in hip fracture patients, offering insights crucial for targeted interventions combating age-related muscle decline and improving musculoskeletal health.
3.Corrigendum: Korean treatment recommendations for patients with axial spondyloarthritis
Mi Ryoung SEO ; Jina YEO ; Jun Won PARK ; Yeon-Ah LEE ; Ju Ho LEE ; Eun Ha KANG ; Seon Mi JI ; Seong-Ryul KWON ; Seong-Kyu KIM ; Tae-Jong KIM ; Tae-Hwan KIM ; Hye Won KIM ; Min-Chan PARK ; Kichul SHIN ; Sang-Hoon LEE ; Eun Young LEE ; Hoon Suk CHA ; Seung Cheol SHIM ; Youngim YOON ; Seung Ho LEE ; Jun Hong LIM ; Han Joo BAEK ;
Journal of Rheumatic Diseases 2024;31(1):62-63
4.Korean treatment recommendations for patients with axial spondyloarthritis
Mi Ryoung SEO ; Jina YEO ; Jun Won PARK ; Yeon-Ah LEE ; Ju Ho LEE ; Eun Ha KANG ; Seon Mi JI ; Seong-Ryul KWON ; Seong-Kyu KIM ; Tae-Jong KIM ; Tae-Hwan KIM ; Hye Won KIM ; Min-Chan PARK ; Kichul SHIN ; Sang-Hoon LEE ; Eun Young LEE ; Hoon Suk CHA ; Seung Cheol SHIM ; Youngim YOON ; Seung Ho LEE ; Jun Hong LIM ; Han Joo BAEK ;
The Korean Journal of Internal Medicine 2024;39(1):200-200
5.Korean treatment recommendations for patients with axial spondyloarthritis
Mi Ryoung SEO ; Jina YEO ; Jun Won PARK ; Yeon-Ah LEE ; Ju Ho LEE ; Eun Ha KANG ; Seon Mi JI ; Seong-Ryul KWON ; Seong-Kyu KIM ; Tae-Jong KIM ; Tae-Hwan KIM ; Hye Won KIM ; Min-Chan PARK ; Kichul SHIN ; Sang-Hoon LEE ; Eun Young LEE ; Hoon Suk CHA ; Seung Cheol SHIM ; Youngim YOON ; Seung Ho LEE ; Jun Hong LIM ; Han Joo BAEK ;
Journal of Rheumatic Diseases 2023;30(3):151-169
We aimed to develop evidence-based recommendations for treating axial spondylarthritis (axSpA) in Korea. The development committee was constructed, key clinical questions were determined, and the evidence was searched through online databases including MEDLINE, Embase, Cochrane, KoreaMed, and KMbase. Systematic literature reviews were conducted, quality of evidence was determined, and draft recommendations were formulated according to the Grading of Recommendations Assessment, Development, and Evaluations methodology. Recommendations that reached 80% consensus among a voting panel were finalized. Three principles and 21 recommendations were determined. Recommendations 1 and 2 pertain to treatment strategies, regular disease status assessment, and rheumatologist-steered multidisciplinary management. Recommendations 3 and 4 strongly recommend patient education, exercise, and smoking cessation. Recommendations 5~12 address pharmacological treatment of active disease using nonsteroidal anti-inflammatory drugs, glucocorticoids, sulfasalazine, biologics, and Janus kinase inhibitors.Recommendations 13~16 address treatment in stable disease. We suggest against spa and acupuncture as therapies (Recommendation 17). Recommendations 18 and 19 pertain to total hip arthroplasty and spinal surgery. Monitoring of comorbidities and drug toxicities are recommended (Recommendations 20 and 21). Recommendations for axSpA treatment in a Korean context were developed based on comprehensive clinical questions and evidence. These are intended to guide best practice in the treatment of axSpA.
6.Korean treatment recommendations for patients with axial spondyloarthritis
Mi Ryoung SEO ; Jina YEO ; Jun Won PARK ; Yeon-Ah LEE ; Ju Ho LEE ; Eun Ha KANG ; Seon Mi JI ; Seong-Ryul KWON ; Seong-Kyu KIM ; Tae-Jong KIM ; Tae-Hwan KIM ; Hye Won KIM ; Min-Chan PARK ; Kichul SHIN ; Sang-Hoon LEE ; Eun Young LEE ; Hoon Suk CHA ; Seung Cheol SHIM ; Youngim YOON ; Seung Ho LEE ; Jun Hong LIM ; Han Joo BAEK ;
The Korean Journal of Internal Medicine 2023;38(5):620-640
We aimed to develop evidence-based recommendations for treating axial spondylarthritis (axSpA) in Korea. The development committee was constructed, key clinical questions were determined, and the evidence was searched through online databases including MEDLINE, Embase, Cochrane, KoreaMed, and Kmbase. Systematic literature reviews were conducted, quality of evidence was determined, and draft recommendations were formulated according to the Grading of Recommendations Assessment, Development, and Evaluations methodology. Recommendations that reached 80% consensus among a voting panel were finalized. Three principles and 21 recommendations were determined. Recommendations 1 and 2 pertain to treatment strategies, regular disease status assessment, and rheumatologist-steered multidisciplinary management. Recommendations 3 and 4 strongly recommend patient education, exercise, and smoking cessation. Recommendations 5–12 address pharmacological treatment of active disease using nonsteroidal anti-inflammatory drugs, glucocorticoids, sulfasalazine, biologics, and Janus kinase inhibitors. Recommendations 13–16 address treatment in stable disease. We suggest against spa and acupuncture as therapies (Recommendation 17). Recommendations 18 and 19 pertain to total hip arthroplasty and spinal surgery. Monitoring of comorbidities and drug toxicities are recommended (Recommendations 20 and 21). Recommendations for axSpA treatment in a Korean context were developed based on comprehensive clinical questions and evidence. These are intended to guide best practice in the treatment of axSpA.
7.Genetic Screening for Chromosomal Abnormalities and Y Chromosome Microdeletions in 846 Infertile Korean Men.
Sung Hee HAN ; Chong Won BAK ; Hyunseok CHO ; Ga Weo BAN ; Jeom Soon KANG ; Hwan Sub LIM ; Kyoung Ryul LEE ; Seung Yong HWANG
Laboratory Medicine Online 2018;8(4):148-155
BACKGROUND: Chromosomal abnormalities are confirmed as one of the frequent causes of male infertility. The microdeletion of the azoospermia factor (AZF) region in the Y chromosome was discovered as another frequent genetic cause associated with male infertility. The aim of this study was to evaluate the frequency and type of chromosomal abnormalities and Y chromosome microdeletions in Korean infertile men. METHODS: A total of 846 infertile men with azoospermia and severe oligozoospermia were included for genetic screening. Cytogenetic analyses using G-banding and screening for Y chromosome microdeletions by multiplex PCR for AZF genes were performed. RESULTS: Chromosomal abnormalities were detected in 112 infertile men (13.2%). Of these, Klinefelter's syndrome was the most common (55.4%, 62/112), followed by balanced translocation including translocation between sex chromosome and autosome (14.3%), Yq deletion (13.4%), X/XY mosaicism with Yq deletion (12.5%), and XX male (4.5%). The overall prevalence of Y chromosome microdeletions was 9.2% (78/846). Most microdeletions were in the AZFc region (51.3%) with a low incidence in AZFa (7.7 %) and AZFb (6.4 %). Combined deletions involving the AZFbc and AZFabc regions were detected in 26.9 % and 7.7 % of men, respectively. Among the infertile men with Y chromosome microdeletions, the incidence of chromosomal abnormality was 25.6% (20/78). CONCLUSIONS: There was a high incidence (20.1%) of chromosomal abnormalities and Y chromosome microdeletions in Korean infertile men. These findings strongly suggest that genetic screening for chromosomal abnormalities and Y chromosome microdeletions should be performed, and genetic counseling should be provided before starting assisted reproductive techniques.
Azoospermia
;
Chromosome Aberrations*
;
Cytogenetic Analysis
;
Genetic Counseling
;
Genetic Testing*
;
Humans
;
Incidence
;
Infertility, Male
;
Klinefelter Syndrome
;
Male
;
Mass Screening
;
Mosaicism
;
Multiplex Polymerase Chain Reaction
;
Oligospermia
;
Prevalence
;
Reproductive Techniques, Assisted
;
Sex Chromosomes
;
Y Chromosome*
8.Valsartan 160 mg/Amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate Response to Amlodipine 5 mg Monotherapy.
Jidong SUNG ; Jin Ok JEONG ; Sung Uk KWON ; Kyung Heon WON ; Byung Jin KIM ; Byung Ryul CHO ; Myeong Kon KIM ; Sahng LEE ; Hak Jin KIM ; Seong Hoon LIM ; Seung Woo PARK ; Jeong Euy PARK
Korean Circulation Journal 2016;46(2):222-228
BACKGROUND AND OBJECTIVES: When monotherapy is inadequate for blood pressure control, the next step is either to continue monotherapy in increased doses or to add another antihypertensive agent. However, direct comparison of double-dose monotherapy versus combination therapy has rarely been done. The objective of this study is to compare 10 mg of amlodipine with an amlodipine/valsartan 5/160 mg combination in patients whose blood pressure control is inadequate with amlodipine 5 mg. SUBJECTS AND METHODS: This study was conducted as a multicenter, open-label, randomized controlled trial. Men and women aged 20-80 who were diagnosed as having hypertension, who had been on amlodipine 5 mg monotherapy for at least 4 weeks, and whose daytime mean systolic blood pressure (SBP) ≥135 mmHg or diastolic blood pressure (DBP) ≥85 mmHg on 24-hour ambulatory blood pressure monitoring (ABPM) were randomized to amlodipine (A) 10 mg or amlodipine/valsartan (AV) 5/160 mg group. Follow-up 24-hour ABPM was done at 8 weeks after randomization. RESULTS: Baseline clinical characteristics did not differ between the 2 groups. Ambulatory blood pressure reduction was significantly greater in the AV group compared with the A group (daytime mean SBP change: -14±11 vs. -9±9 mmHg, p<0.001, 24-hour mean SBP change: -13±10 vs. -8±8 mmHg, p<0.0001). Drug-related adverse events also did not differ significantly (A:AV, 6.5 vs. 4.5%, p=0.56). CONCLUSION: Amlodipine/valsartan 5/160 mg combination was more efficacious than amlodipine 10 mg in hypertensive patients in whom monotherapy of amlodipine 5 mg had failed.
Amlodipine*
;
Blood Pressure
;
Blood Pressure Monitoring, Ambulatory
;
Female
;
Follow-Up Studies
;
Humans
;
Hypertension
;
Male
;
Random Allocation
9.The first private-hospital based proton therapy center in Korea; status of the Proton Therapy Center at Samsung Medical Center.
Kwangzoo CHUNG ; Youngyih HAN ; Jinsung KIM ; Sung Hwan AHN ; Sang Gyu JU ; Sang Hoon JUNG ; Yoonsun CHUNG ; Sungkoo CHO ; Kwanghyun JO ; Eun Hyuk SHIN ; Chae Seon HONG ; Jung Suk SHIN ; Seyjoon PARK ; Dae Hyun KIM ; Hye Young KIM ; Boram LEE ; Gantaro SHIBAGAKI ; Hideki NONAKA ; Kenzo SASAI ; Yukio KOYABU ; Changhoon CHOI ; Seung Jae HUH ; Yong Chan AHN ; Hong Ryull PYO ; Do Hoon LIM ; Hee Chul PARK ; Won PARK ; Dong Ryul OH ; Jae Myung NOH ; Jeong Il YU ; Sanghyuk SONG ; Ji Eun LEE ; Bomi LEE ; Doo Ho CHOI
Radiation Oncology Journal 2015;33(4):337-343
PURPOSE: The purpose of this report is to describe the proton therapy system at Samsung Medical Center (SMC-PTS) including the proton beam generator, irradiation system, patient positioning system, patient position verification system, respiratory gating system, and operating and safety control system, and review the current status of the SMC-PTS. MATERIALS AND METHODS: The SMC-PTS has a cyclotron (230 MeV) and two treatment rooms: one treatment room is equipped with a multi-purpose nozzle and the other treatment room is equipped with a dedicated pencil beam scanning nozzle. The proton beam generator including the cyclotron and the energy selection system can lower the energy of protons down to 70 MeV from the maximum 230 MeV. RESULTS: The multi-purpose nozzle can deliver both wobbling proton beam and active scanning proton beam, and a multi-leaf collimator has been installed in the downstream of the nozzle. The dedicated scanning nozzle can deliver active scanning proton beam with a helium gas filled pipe minimizing unnecessary interactions with the air in the beam path. The equipment was provided by Sumitomo Heavy Industries Ltd., RayStation from RaySearch Laboratories AB is the selected treatment planning system, and data management will be handled by the MOSAIQ system from Elekta AB. CONCLUSION: The SMC-PTS located in Seoul, Korea, is scheduled to begin treating cancer patients in 2015.
Cyclotrons
;
Helium
;
Humans
;
Korea*
;
Metallurgy
;
Particle Accelerators
;
Patient Positioning
;
Proton Therapy*
;
Protons*
;
Radiation Oncology
;
Respiratory System
;
Seoul
10.The Combination of Real-Time PCR and HPLC for the Identification of Non-Tuberculous Mycobacteria.
Jae Sun PARK ; Jung In CHOI ; Ji Hun LIM ; Jong Joon AHN ; Yangjin JEGAL ; Kwang Won SEO ; Seung Won RA ; Jae Bum JEON ; Seon Ho LEE ; Sung Ryul KIM ; Joseph JEONG
Annals of Laboratory Medicine 2013;33(5):349-352
We used HPLC and AdvanSure real-time PCR (LG Life Sciences, Korea) to retrospectively analyze non-tuberculous mycobacteria (NTM) in 133 clinical specimens. The specimens were culture-positive for NTM and the HPLC method identified 130 strains of mycobacteria from the cultures (97.7%) at the species level. Among the isolates, 48 Mycobacterium. kansasii (36.1%), 39 M. intracellulare (29.3%), 17 M. avium (12.8%), 16 M. abscessus (12.0%), 6 M. fortuitum (4.5%), 2 M. szulgai (1.5%), 2 M. gordonae (1.5%), and 3 unclassified NTM strains (2.3%) were identified. The real-time PCR assay identified 60 NTM-positive specimens (45.1%), 65 negative specimens (48.9%), and 8 M. tuberculosis (TB)-positive specimens (6.0%). The real-time PCR assay is advantageous because of its rapid identification of NTM. However, in our study, the real-time PCR assay showed relatively low sensitivity (45.1%) when using direct specimens including sputum and bronchoalveolar lavage (BAL) fluid. HPLC is useful as it discriminates NTM at the species level, although it is time-consuming and requires specific equipment and technical expertise. A combination of both methods will be helpful for the rapid and accurate identification of mycobacteria in clinical laboratories.
Aged
;
Aged, 80 and over
;
Bronchoalveolar Lavage Fluid/microbiology
;
*Chromatography, High Pressure Liquid
;
DNA, Bacterial/genetics
;
Female
;
Humans
;
Male
;
Middle Aged
;
Mycobacterium/*genetics/isolation & purification
;
Mycobacterium Infections/diagnosis/*microbiology
;
*Real-Time Polymerase Chain Reaction
;
Sputum/microbiology

Result Analysis
Print
Save
E-mail